

# Press Release

New Brunswick, New Jersey  
April, 14th 2021

Ensuring the safety and health of our consumers and employees is our number one priority. In order to continue practicing this value, we have paused our vaccine distribution in the United States and a few countries abroad, in response to the six cases which have prompted a rare disorder involving blood clots – events which we have remained cognizant of and are actively monitoring.

We look forward to effectively cooperating and working with the CDC and FDA to investigate this matter, and appreciate the patience of those involved in the vaccine process – from researchers and distributors to those seeking the vaccine. We also applaud and want to thank the CDC and FDA for investigating this matter – their actions uphold the health-care sector’s collective goal of guaranteeing the safety of all vaccines currently available in the market and currently unvaccinated individuals.

Transparency and clear communication is valued within our company culture and crucial in the pharmaceutical industry. As such, we have created a section on our website which includes frequently asked questions, contact information, and other official statements. As a United States-based organization, this website will be updated continuously throughout the remainder of the coronavirus public health emergency declaration in the United States.

We also encourage individuals to visit the CDC and FDA websites for additional information and to follow our social media channels for the latest updates. In particular, for individuals who have received one of the 6.8 million distributed vaccines, we encourage those with health-related concerns to bring them forward to their health care provider. For further information or methods of contact, please [visit our page](#).

---